Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents
Authors:
- Maike Scherf-ClavelMSMaike Scherf-Clavel
- Stefanie FeketeSFStefanie Fekete
- Manfred GerlachMGManfred Gerlach
- Christoph U. CorrellCCChristoph U. Correll
- Paul PlenerPPPaul Plener
- Jörg M. FegertJörg M. Fegert
- Andreas KarwautzAndreas Karwautz
- Peter HeuschmannPHPeter Heuschmann
- Tobias BanaschewskiTBTobias Banaschewski
- Wolfgang BriegelWolfgang Briegel
- Christian FleischhakerCFChristian Fleischhaker
- Tobias HellenschmidtTHTobias Hellenschmidt
Open Access
- 30 July 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 983
Abstract
Introduction: Sex-specific differences in psychopharmacological treatment have gained increasing attention in adults, with studies showing that women often have higher serum concentrations of psychotropic drugs due to biological differences. However, despite recognition of these differences in adults, reference ranges for therapeutic drug monitoring (TDM) in general, but even more sex-specific therapeutic windows for psychotropic drugs, are lacking in children and adolescents, who may metabolize and respond to medications differently. Aim: The study aimed to investigate sex-specific differences in antidepressant (AD) and antipsychotic (AP) -treatment outcomes, and pharmacokinetics in childhood/adolescence. In particular, we examined differences in AD and AP serum levels and clinical effects, including adverse drug effects (ADEs) and therapeutic effectiveness. Methods: This study is part of the multicenter “TDM-VIGIL” pharmacovigilance project, which prospectively followed patients aged 6–18 years treated with AD and AP across 18 child psychiatric centers in German-speaking countries from 2014 to 2018. Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Statistical analyses were performed to examine sex differences in pharmacokinetics and clinical responses, adjusting for age, weight, and other confounders. Results: A total of 705 patients (66.5% girls, 24.7% p = 0.04), as well as with moderate treatment response (p = 0.02) compared to no treatment response. Discussion: Our findings suggest that sex may not affect serum levels of investigated AD and AP in children/adolescents. However, treatment outcome of fluoxetine was associated with sex, with higher probability for a better outcome in female patients diagnosed with mood (affective) disorders.Keywords
Funding Information
- German Federal Institute for Drugs and Medical Devices (V-15322/68605/2013-2018, 001EZ0937)
- German Federal Ministry of Education and Research (V-15322/68605/2013-2018, 001EZ0937)
- Verein zur Durchführung Neurowissenschaftlicher Tagungen e.V. (V-15322/68605/2013-2018, 001EZ0937)
This publication has 41 references indexed in Scilit:
- Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance studyJournal of Neural Transmission, 2024
- The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorderJournal of Psychiatric Research, 2023
- Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidoneJournal of Neural Transmission, 2022
- Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorderComprehensive Psychiatry, 2022
- Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiaprideEuropean Journal of Clinical Pharmacology, 2020
- Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practiceJournal of Neural Transmission, 2016
- Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012European Neuropsychopharmacology, 2016
- Effects of gender and age on serum concentrations of antidepressants under naturalistic conditionsJournal of Neural Transmission, 2012
- Lifetime Prevalence of Mental Disorders in U.S. Adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A)Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- Depression in children and adolescents: Does gender make a difference?Current Psychiatry Reports, 2006